OVERVIEW

Basal Insulin in Vulnerable Patients with Type 2 Diabetes is organized by CMEducation Resources, LLC and will be held from Jul 18, 2017 - Jul 18, 2019. This CME Conference has been approved for a maximum of 2.50 AMA PRA Category 1 Credits.

Course Overview :
In this web-based program, physicians and optometrists will learn how recent developments have helped to advance the management of Type 2 diabetes

Conference Objectives are :
Upon completion of this activity, participants will be able to:
• Apply national guidelines, including the non-strictly algorithmic and flexibly prescriptive 2012 ADA/ EASD Guidelines focused on comprehensive management of diabetes; and identify therapeutic options, based on objective triggers—number and type of OADs, patient needs and preferences, target goal attainment, and other factors—consisting of oral, basal insulin-, and/or combined oral-insulin regimens that provide guideline-consistent care for this population.
• Explain the physiologic basis of long-acting insulin formulations and how mimicking physiologic insulin triggers and time-activity profiles may improve efficacy and safety of long-acting formulations;
• Identify patients with T2D who are not meeting target goals for HbA1 and/or other targets require initiation with or who require intensification with basal insulin therapy;
• Assess and calculate the risks of hypoglycemia in their patients with T2D, counsel their patients on recognizing symptoms of hypoglycemia, and select among therapeutic agents, including established and longer-acting basal insulin-based therapies and combination oral-insulin-based treatments that may reduce the risk of hypoglycemia in this patient subgroup;
• Understand how new basal insulin formulations in development or recently introduced into clinical use may help reduce the risk of hypoglycemia associated with insulin use;

Additional details will be posted as soon as they are available.